[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001280640A1 - Peptides as ns3-serine protease inhibitors of hepatitis c virus - Google Patents

Peptides as ns3-serine protease inhibitors of hepatitis c virus

Info

Publication number
AU2001280640A1
AU2001280640A1 AU2001280640A AU8064001A AU2001280640A1 AU 2001280640 A1 AU2001280640 A1 AU 2001280640A1 AU 2001280640 A AU2001280640 A AU 2001280640A AU 8064001 A AU8064001 A AU 8064001A AU 2001280640 A1 AU2001280640 A1 AU 2001280640A1
Authority
AU
Australia
Prior art keywords
hepatitis
peptides
virus
protease inhibitors
serine protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280640A
Inventor
Ashok Arasappan
Frank Bennett
Stephane L. Bogen
Terence K. Brunck
Ashit K. Ganguly
Viyyoor Moopil Girijavallabhan
Edwin E. Jao
Scott Jeffrey Kemp
Odile Esther Levy
Marguerita Lim-Wilby
Yi-Tsung Liu
Raymond G. Lovey
Jinping Mccormick
F. George Njoroge
Tejal Parekh
Russell E Pike
Patrick A. Pinto
Anil K. Saksena
Haiyan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Dendreon Pharmaceuticals LLC
Original Assignee
Schering Corp
Corvas International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Corvas International Inc filed Critical Schering Corp
Publication of AU2001280640A1 publication Critical patent/AU2001280640A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001280640A 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus Abandoned AU2001280640A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22010900P 2000-07-21 2000-07-21
US60/220,109 2000-07-21
PCT/US2001/022826 WO2002008256A2 (en) 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
AU2001280640A1 true AU2001280640A1 (en) 2002-02-05

Family

ID=22822101

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280640A Abandoned AU2001280640A1 (en) 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus

Country Status (7)

Country Link
US (2) US6800434B2 (en)
EP (1) EP1301528A2 (en)
JP (2) JP2004515465A (en)
AR (1) AR029851A1 (en)
AU (1) AU2001280640A1 (en)
CA (1) CA2418204A1 (en)
WO (1) WO2002008256A2 (en)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268391A1 (en) 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
AR029851A1 (en) * 2000-07-21 2003-07-16 Dendreon Corp NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C
HU229997B1 (en) 2000-07-21 2015-04-28 Dendreon Corp San Diego Peptides as ns3-serine protease inhibitors of hepatitis c virus
SV2003000617A (en) * 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
EP1467989B1 (en) 2002-01-23 2009-09-23 Schering Corporation Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatitis c virus infection
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
WO2003087092A2 (en) 2002-04-11 2003-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
AP2005003212A0 (en) 2002-06-28 2005-03-31 Centre Nat Rech Scient Modified 2' and 3' nucleoside prodrugs for treating flaviviridae infections.
AU2003277891A1 (en) * 2002-09-23 2004-04-08 Medivir Ab Hcv ns-3 serine protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
AU2011203054B2 (en) * 2003-04-11 2012-04-26 Vertex Pharmaceuticals, Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
AU2004230946A1 (en) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CN103203010A (en) 2003-05-21 2013-07-17 贝林格尔.英格海姆国际有限公司 Pharmaceutical Compositions Comprising Hepatitis C Inhibitor Compounds
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
PE20050251A1 (en) * 2003-07-18 2005-04-13 Vertex Pharma SERINE PROTEASE INHIBITORS, ESPECIALLY HCV PROTEASE NS3-NS4A
CN1852915A (en) 2003-07-25 2006-10-25 艾登尼科斯（开曼）有限公司 Purine nucleoside analogues for treating flaviviridae including hepatitis c
MXPA06002250A (en) 2003-08-26 2006-05-17 Schering Corp Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus.
UY28500A1 (en) * 2003-09-05 2005-04-29 Vertex Pharma INHIBITORS OF SERINE PROTEASES, IN PARTICULAR PROTEASA NS3-NS4A HCV.
EP1664091A1 (en) * 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MXPA06003455A (en) 2003-09-26 2006-05-31 Schering Corp Macrocyclic inhibitors of hepatitis c virus ns3 serine protease.
KR20120010278A (en) 2003-10-10 2012-02-02 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
EP1689770A1 (en) 2003-11-20 2006-08-16 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
EP2311851A3 (en) 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
SI1719773T1 (en) 2004-02-24 2009-08-31 Japan Tobacco Inc Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
WO2005087730A1 (en) 2004-02-27 2005-09-22 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005085275A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
CA2557247A1 (en) 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
JP4714732B2 (en) 2004-02-27 2011-06-29 シェーリング コーポレイション Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
DE602005023224D1 (en) 2004-02-27 2010-10-07 Schering Corp Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
ES2328596T3 (en) 2004-05-20 2009-11-16 Schering Corporation PROLINES REPLACED AS INHIBITORS OF SERINA PROTEASA OF VIRUS NS3 OF HEPATITIS C.
EP1773348A4 (en) * 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc Tetrapeptide analogs
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
US7550559B2 (en) 2004-08-27 2009-06-23 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
NZ563361A (en) 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
WO2006130628A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Combination of hcv protease inhibitors with a surfactant
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
KR20080031281A (en) * 2005-06-16 2008-04-08 노파르티스 아게 Lactam containing hcv inhibitors
AR054778A1 (en) 2005-06-17 2007-07-18 Novartis Ag USE OF SANGLIFERINA IN HCV
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
ME01318B (en) 2005-07-29 2013-12-20 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
CN101273052B (en) 2005-07-29 2016-01-13 爱尔兰詹森科学公司 The macrocyclic hcv inhibitors of hepatitis C virus
CA2617679A1 (en) 2005-08-02 2007-02-08 Steve Lyons Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
EP2364970A1 (en) 2005-08-19 2011-09-14 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (en) * 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
WO2007059221A2 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals, Inc Hepatitis c virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
PT1966130E (en) 2005-12-23 2014-01-30 Zealand Pharma As Modified lysine-mimetic compounds
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
MX2008010355A (en) * 2006-02-09 2008-10-31 Schering Corp Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto.
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
MX2008012225A (en) * 2006-03-23 2008-12-03 Schering Corp Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto.
KR101059593B1 (en) * 2006-04-11 2011-08-25 노파르티스 아게 HCl / HIV inhibitors and uses thereof
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
RU2009109355A (en) 2006-08-17 2010-09-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) OUTLET POLYMERASE INHIBITORS
EP2099430A2 (en) * 2006-12-07 2009-09-16 Schering Corporation Ph sensitive matrix formulation
EP2074087A2 (en) 2006-12-21 2009-07-01 Wyeth Synthesis of pyrrolidine compounds
CN101611002A (en) * 2006-12-22 2009-12-23 先灵公司 Be used for the treatment of or prevent 4 of HCV and related viral infections, 5-ring annulated indole derivatives
WO2008082484A1 (en) 2006-12-22 2008-07-10 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
ATE543808T1 (en) 2006-12-22 2012-02-15 Schering Corp 5,6-RING-ANNELATED INDOLE DERIVATIVES AND USE THEREOF
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
NZ579442A (en) * 2007-02-27 2012-02-24 Vertex Pharma Co-crystals of VX-950 (telaprevir) and other components, and pharmaceutical compositions comprising the same
CA2696053A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2008248116A1 (en) 2007-05-04 2008-11-13 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int Viral polymerase inhibitors
WO2009032125A1 (en) * 2007-08-29 2009-03-12 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
KR20100067652A (en) 2007-08-29 2010-06-21 쉐링 코포레이션 Substituted indole derivatives and methods of use thereof
US8143305B2 (en) * 2007-08-29 2012-03-27 Schering Corporation 2,3-substituted indole derivatives for treating viral infections
CA2704284A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CN102317285A (en) * 2007-11-16 2012-01-11 先灵公司 Substituted indole derivatives of 3-amino-sulfonyl and method of use thereof
JP5249344B2 (en) * 2007-11-16 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション Indole derivatives substituted at the 3-position of the heterocyclic ring and use thereof
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int Viral polymerase inhibitors
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
KR20150117305A (en) * 2007-12-21 2015-10-19 셀진 아빌로믹스 리서치, 인코포레이티드 HCV protease inhibitors and uses thereof
US8309685B2 (en) * 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
NZ586232A (en) * 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
MX2010008523A (en) 2008-02-04 2010-08-31 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors.
MX2010010276A (en) 2008-03-20 2011-03-25 Enanta Pharm Inc Fluorinated macrocyclic compounds as hepatitis c virus inhibitors.
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
CN102159579B (en) * 2008-06-13 2015-03-25 默沙东公司 Tricyclic indole derivatives and methods of use thereof
TW201004632A (en) 2008-07-02 2010-02-01 Idenix Pharmaceuticals Inc Compounds and pharmaceutical compositions for the treatment of viral infections
AU2009282574B2 (en) 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8541434B2 (en) 2008-08-20 2013-09-24 Merck Sharp & Dohme Corp. Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5731976B2 (en) 2008-08-20 2015-06-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Substituted pyridine derivatives and substituted pyrimidine derivatives and their use in the treatment of viral infections
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Sciences, Inc. Nucleoside phosphoramidates
CA2750227A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
JP2013501068A (en) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド Macrocyclic serine protease inhibitor
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011066241A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
BR112012014899A2 (en) 2009-12-18 2017-03-14 Idenix Pharmaceuticals Inc compound, pharmaceutical composition, method for treating or preventing hepatitis c virus infection in a subject, method for treating, preventing or ameliorating one or more symptoms of a liver disease or disorder associated with hepatitis c virus infection in a subject , method for inhibiting replication of a virus in a host, method for inhibiting replication of a virus
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
ES2558554T3 (en) 2010-03-09 2016-02-05 Merck Sharp & Dohme Corp. Condensed tricyclic silyl compounds and methods of their use for the treatment of viral diseases
HUE034239T2 (en) 2010-03-31 2018-02-28 Gilead Pharmasset Llc Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
CA2795054A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2598149A4 (en) 2010-07-26 2014-09-10 Merck Sharp & Dohme Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
JP2013540122A (en) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション Fused tetracyclic compound derivatives and methods of use thereof for the treatment of viral diseases
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
JP6069215B2 (en) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー Compound
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
PE20140522A1 (en) 2011-04-13 2014-05-03 Merck Sharp & Dohme DERIVATIVES OF NUCLEOSIDES 2'- SUBSTITUTED AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
CN103906759A (en) 2011-09-12 2014-07-02 埃迪尼克斯医药公司 Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
RS56975B1 (en) 2011-09-16 2018-05-31 Gilead Pharmasset Llc Methods for treating hcv
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
CN104254518A (en) 2012-02-16 2014-12-31 阿奇克斯制药公司 Linear peptide antibiotics
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
US20130315868A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
TR201809048T4 (en) 2012-10-08 2018-07-23 Centre Nat Rech Scient 2'-chloro nucleoside analogs for HCV infection.
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
EP2938624A1 (en) 2012-11-14 2015-11-04 IDENIX Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
EP3113763A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
CN104293844B (en) * 2014-08-26 2017-10-10 苏州永健生物医药有限公司 A kind of synthetic method of Telaprevir intermediate
MX2018016189A (en) 2016-06-21 2019-06-10 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives.
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
US11324799B2 (en) 2017-05-05 2022-05-10 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496927A (en) * 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
BR8807310A (en) 1987-11-18 1990-03-13 Chiron Corp POLINUCLEOTIDIO, POLINUCLEOTIDIO RECOMBINANT, RECOMBINANT VECTOR, CELL HOSTESS, EXPRESSION SYSTEM RECOMBINANT, CELL TRANSFORMED, polypeptide, HCV, DE polypeptide PREPARATION, polypeptide OF HCV polypeptide PURIFIED, polypeptide RECOMBINANT, DE FUSION polypeptide, MONOCLONAL ANTIBODY, PREPARATION PURIFIED ANTIBODY POLYCLONAL, PARTICLE, POLYNUCLEOTID PROBE, ANTIBODY KIT FOR HCV EPETOPE, METHOD FOR POLYPEPTIDY PRODUCTION, METHOD FOR DETECTING HCV NUCLEIC ACIDS, IMMUNOENSAIO TO DETECT HCV ANTIGENE, IMMUNOENSAIO DETECTORIGIO ANTIGENE OF HCV, CELL, CELL INFECTED WITH HCV, METHOD FOR THE PRODUCTION OF ANTIBODIES FOR HCV AND METHOD FOR ISOLATING CDNA DERIVED FROM THE GENOME FROM AN UNIDENTIFIED INFECTIOUS AGENT
DK0381216T3 (en) 1989-02-01 1996-05-13 Asahi Glass Co Ltd Azeotrope or azeotrope-like chlorofluorocarbon hydride mixture
US5359138A (en) * 1989-04-15 1994-10-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
WO1990012805A1 (en) * 1989-04-15 1990-11-01 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Postostatin and related compound thereof, or their salts
EP0527788B1 (en) 1990-04-04 2004-06-30 Chiron Corporation Hepatitis c virus protease
WO1993015193A1 (en) * 1992-01-31 1993-08-05 Abbott Laboratories Mammalian expression systems for hcv proteins
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
US5414018A (en) * 1993-09-24 1995-05-09 G. D. Searle & Co. Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension
US5843450A (en) * 1994-02-14 1998-12-01 Abbott Laboratories Hepatitis GB Virus synthetic peptides and uses thereof
IT1272179B (en) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLITHIC ACTIVITY OF THE NS3 PROTEASE OF THE VIRUS HCV.
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
US5763576A (en) * 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
CA2268391A1 (en) * 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
HUP0100100A3 (en) * 1997-08-11 2001-12-28 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use
GB9809664D0 (en) * 1998-05-06 1998-07-01 Hoffmann La Roche a-Ketoamide derivatives
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (en) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH .
JP2000256396A (en) 1999-03-03 2000-09-19 Dainippon Pharmaceut Co Ltd Heterocyclic compound, its intermediate and elastase inhibitor
CA2390349A1 (en) 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
JP4806154B2 (en) 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitors of serine proteases, especially hepatitis C virus NS3 protease
AR029851A1 (en) * 2000-07-21 2003-07-16 Dendreon Corp NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C

Also Published As

Publication number Publication date
WO2002008256A2 (en) 2002-01-31
US20030036501A1 (en) 2003-02-20
WO2002008256A3 (en) 2002-08-29
EP1301528A2 (en) 2003-04-16
CA2418204A1 (en) 2002-01-31
JP2009057390A (en) 2009-03-19
JP2004515465A (en) 2004-05-27
US20050059606A1 (en) 2005-03-17
AR029851A1 (en) 2003-07-16
US6800434B2 (en) 2004-10-05

Similar Documents

Publication Publication Date Title
AU2001280640A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001277967A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
HK1058047A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
IL153669A0 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2002230763A1 (en) Inhibitors of hepatitis c virus ns3 protease
AU2001245356A1 (en) Inhibitors of hepatitis c virus ns3 protease
IL155842A0 (en) Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
AU2001282922A1 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
IL162815A0 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AU5788800A (en) Peptide boronic acid inhibitors of hepatitis c virus protease
AU6371900A (en) Lactam inhibitors of hepatitis c virus ns3 protease
AU2002230764A1 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
AU2003259155A1 (en) Pharmaceutical compositions comprising hepatitis c viral protease inhibitors
GB0107924D0 (en) Inhibitor of hepatitis C virus NS3 protease
HK1023779A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
IL151934A0 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AU2003277891A1 (en) Hcv ns-3 serine protease inhibitors
EP1141255A4 (en) Modified forms of hepatitis c virus ns3 protease
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
AU2002350322A1 (en) Inhibitors of hepatitis c virus protease
AU2002308200A1 (en) Peptides and their use as inhibitors of hepatitis c virus ns3 protease
AU2001254670A1 (en) Detection of hepatitis b virus rna
AU2001264856A1 (en) Inhibitors of viral infection